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Mind the Gap: Why Closing the Doughnut Hole Is
Insufficient for Increasing Medicare Beneficiary Access to
Oral Chemotherapy
Stacie B. Dusetzina and Nancy L. Keating
A B S T R A C T
Purpose
Orally administered anticancer medications are among the fastest growing components of cancer
care. These medications are expensive, and cost-sharing requirements for patients can be a barrier
to their use. For Medicare beneficiaries, the Affordable Care Act will close the Part D coverage gap
(doughnut hole), whichwill reduce cost sharing from100% in 2010 to 25% in 2020 for drug spending
above $2,960 until the beneficiary reaches $4,700 in out-of-pocket spending. How much these
changes will reduce out-of-pocket costs is unclear.
Methods
We used the Medicare July 2014 Prescription Drug Plan Formulary, Pharmacy Network, and Pricing
Information Files from the Centers for Medicare & Medicaid Services for 1,114 stand-alone and
2,230 Medicare Advantage prescription drug formularies, which represent all formularies in 2014.
We identified orally administered anticancer medications and summarized drug costs, cost-sharing
designs used by available plans, and the estimated out-of-pocket costs for beneficiaries without low-
income subsidies who take a single drug before and after the doughnut hole closes.
Results
Little variation existed in formulary design across plans and products. The average price per month
for included products was $10,060 (range, $5,123 to $16,093). In 2010, median beneficiary annual
out-of-pocket costs for a typical treatment duration ranged from $6,456 (interquartile range, $6,433
to $6,482) for dabrafenib to $12,160 (interquartile range, $12,102 to $12,262) for sunitinib. With the
assumption that prices remain stable, after the doughnut hole closes, beneficiaries will spend
approximately $2,550 less.
Conclusion
Out-of-pocket costs forMedicare beneficiaries taking orally administered anticancermedications are
high and will remain so after the doughnut hole closes. Efforts are needed to improve affordability of
high-cost cancer drugs for beneficiaries who need them.
J Clin Oncol 34:375-380. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Orally administered anticancer medications are
among the fastest growing category of prescription
drugs.1,2 Spending on anticancer medications and
costs to patients and insurers has been the focus of
intense debate in recent years.2-8 Historically, many
cancer therapies were physician administered, but
medical innovations have increased the number of
orally administered anticancer therapies. These
innovations allow patients to receive treatments at
home rather than in the clinic, which increases
convenience for patients who need long-term
therapy.9,10 This shift away from physician-
administered medication has also shifted insurers’
reimbursement of these treatments from patients’
medical benefits to their outpatient pharmacy
benefits, which has important implications for
patients’ total out-of-pocket costs.11,12
Cancer is disproportionately a disease of
older adults; thus, Medicare Part D is a key payer
for orally administered anticancer medications.
Traditional Medicare is composed of three parts:
A, B, and D, which correspond to hospital, out-
patient, and prescription drug coverage, respec-
tively. Medicare Parts A and B have been available
as part of the public insurance plan since 1966,
whereas Medicare Part D is offered through
private health insurance and has only been
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available since 2006. Given the increasing availability of oral cancer
medications, a large and growing proportion of anticancer med-
ications are now reimbursed through Medicare Part D.
Although the Affordable Care Act (ACA) includes many pro-
visions to improve affordability of health care services, most of the
changes focus on the privately insured market. One key change
introduced in the ACA forMedicare beneficiaries is the closing of the
Part D coverage gap (ie, the doughnut hole), which has been praised
as a way to reduce out-of-pocket spending for Medicare enrollees. In
2010, before implementation of the ACA, the standardMedicare Part
D benefit included a deductible of $310, 25% coinsurance up to an
initial coverage limit of $2,830, 100% coinsurance for drugs pur-
chased during the doughnut hole (for drug spending. $2,830 until
a patient reached $4,550 in out-of-pocket spending), and 5%
coinsurance in the catastrophic phase.13 This benefit cycle resets at
the beginning of each calendar year. With the ACA, beginning in
2011, the Part D benefit design changes annually to decrease out-of-
pocket costs to patients during the doughnut hole from 100% to
25% coinsurance by 2020. This reduction in patient cost sharing in
the doughnut hole is largely due to manufacturers’ 50% discount on
drug prices during the doughnut hole. Contributions made by the
manufacturer during this benefit phase are counted toward the
patient’s out-of-pocket spending, which reduces the amount of time
the patient spends in the doughnut hole (Fig 1).14
We examined the formularies of Medicare Part D plans to better
understand coverage for oral anticancermedications. First, we explored
whether variation exists in the benefits offered for these medications.
Second, we estimated out-of-pocket expenditures for Medicare ben-
eficiaries with Part D coverage who require oral anticancer therapy and
who do not receive low-income subsidies. Finally, we assessed the
extent to which the ACA closing of the doughnut hole will reduce costs
for oral chemotherapy users enrolled in Medicare Part D.
METHODS
We used the July 15, 2014, quarterly release of the Prescription Drug Plan
Formulary, Pharmacy Network, and Pricing Information Files from the
Centers for Medicare & Medicaid Services (CMS formulary files) to
identify Part D coverage for orally administered anticancer medications.
We followed the methodology proposed by Howard et al15 to include
products first approved by the US Food and Drug Administration in 1995
or later and that are administered with the primary intent of improving
overall or progression-free survival. From this subset of products, we
focused on products covered by Medicare Part D in 2014 (Table 1). We
excluded endocrine therapy from consideration (tamoxifen and aromatase
inhibitors) because these drugs are inexpensive relative to the selected
products and primarily available as generic products at this time.
We identified 1,114 stand-alone Part D Plan/Product formularies
(PDPs) and 2,230 Medicare Advantage Part D Plan/Product formularies
(MA-PDs) in the CMS formulary files. Because antineoplastic medications
are a protected class within Medicare Part D, nearly all products studied
were covered on available formularies. For each covered therapy, we
evaluated the formulary structure used by stand-alone PDPs and MA-PDs
to describe variation in benefit design by plan. Next, we estimated ben-
eficiary total out-of-pocket costs for each drug by using the median
duration of therapy expected for each treatment. Median duration of
therapy was based on previously published methodology and data that
used drug product labels, published randomized trial results, and cost-
effectiveness studies (Data Supplement).15 We rounded duration of
therapy to the next full month when a partial month was indicated and
capped use of a product at 12 months given that the benefit design reset
each calendar year.
We obtained the price for a 30-day supply of each included product
at a standard dose directly from the CMS formulary files. These prices
represent the amount reimbursed for the medication (patient, plan,
Medicare contributions) and were used as the input for the out-of-pocket
price calculation for each Part D formulary (Data Supplement). Next, we
predicted the median and interquartile range of out-of-pocket costs for a
Medicare Part D enrollee who takes a single specialty drug for a full course
25% coinsurance
until drug spend reaches
$2,960
100% coinsurance
until out-of-pocket
reaches $4,700
5% coinsurance
until year end
Initial coverage Coverage gap Catastrophic coverage
$310
deductible
2010
2020
$310
deductible
25% coinsurance
until drug spend reaches
$2,960
25% coinsurance + 50%
manufacturer discount
until out-of-pocket
reaches $4,700
5% coinsurance
until year end
Initial coverage Coverage gap Catastrophic coverage
Fig 1. Medicare Part D benefit design and beneficiary cost-sharing requirements in 2010 and 2020. The standard 2014 Medicare Part D benefit included a deductible of
$310, 25% coinsurance up to an initial coverage limit of $2,960, coinsurance for drugs purchased during the doughnut hole (100% in 2010, 25% in 2020) for drug spending
greater than $2,960 until a patient reached $4,700 in out-of-pocket spending, and 5% coinsurance in the catastrophic phase. Although initial coverage limits and out-of-
pocket maximum costs were slightly lower in 2010, we used 2014 limits for all analyses for consistency (by changing only the percentage of coinsurance during the
coverage gap). This benefit cycle resets at the beginning of each calendar year. As part of the Affordable Care Act, beginning in 2011, the Part D benefit design changes
annually to decrease out-of-pocket costs to patients during the doughnut hole. This reduction in patient cost sharing in the doughnut hole is largely due to manufacturers’
50% discount on drug prices during the doughnut hole. Contributions made by the manufacturer during this benefit phase are counted toward patient out-of-pocket
spending, which reduces the amount of time that a patient spends in the doughnut hole. Patient deductibles are shown with dark blue shading, patient coinsurance with
medium blue shading, manufacturer discounts with light blue shading (in 2020 only).
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of treatment (of median duration, capped at 12 months) by using the Part
D initial coverage limit and the out-of-pocket limits in 2015. To assess the
effect of closing the doughnut hole on out-of-pocket costs, we estimated
out-of-pocket costs for 2010 and 2020 (before and after the closing of the
doughnut hole). Specifically, we calculated annual out-of-pocket costs first
by calculating the deductible (if any) plus the coinsurance/copayments for
the initial coverage period up to $2,960 (initial coverage limit). Next, we
calculated the out-of-pocket costs in the doughnut hole (100% in 2010,
25% in 2020) up to $4,700 (out-of-pocket limit before catastrophic
coverage, which includes the 50% manufacturer discount during the
coverage gap in 2020). Finally, we calculated the costs in the catastrophic
period through the end of the benefit year. Because annual out-of-pocket
costs were similar for patients in PDPs and MA-PDs, we present results for
PDPs only unless otherwise indicated.
Sensitivity Analyses
Increases in drug prices have occurred rapidly over the past decade,
although newer policies to increase biologic competition and the intro-
duction of generics could result in price reductions for some therapies.
Because product prices may change over time, we also estimated patient
out-of-pocket prices and potential cost savings by assuming that anticancer
medication prices increased and decreased by 50%, respectively, between
2014 (the prices used in the 2010 estimate) and 2020. Furthermore, to
account for patients who used more or less therapy than the median
duration tested in the primary analysis, we replicated analyses by using a
3- and 12-month duration to mimic minimum and maximum durations
of therapy during a benefit year. Finally, to ensure the robustness of the
drug price data, we re-estimated comparisons of out-of-pocket spending in
2010 and 2020 by using published cost estimates, which were relatively
lower than those identified in the 2014 formulary files.16 Results and the
detailed methodology are included in the Data Supplement. All results
were substantively similar to the primary analysis presented here.
RESULTS
As anticipated, orally administered anticancer therapies were
available on a majority of formularies across both MA-PDs and
stand-alone PDPs. The median total cost for a 30-day supply of
included products (patient and plan contributions) across all
plans was $10,060 (range, $5,123 for lapatinib to $16,093 for
pomalidomide; Table 1). Stand-alone PDP formularies typically
use one of two formulary designs for coverage of oral anticancer
medications as follows: $310 deductible and 25% coinsurance in
the initial coverage period or no deductible and 33% coinsurance
in the initial coverage period. Both designs used the standard 45%
coinsurance in the coverage gap in 2014 and 5% catastrophic
coverage. MA-PDs most often used the latter design (Table 2).
Plan Coverage and Estimated Out-of-Pocket Expenses
Median out-of-pocket costs for Medicare Part D enrollees in
2010 for amedian duration course ranged from $6,456 for dabrafenib
to $12,160 for sunitinibwith the assumption that patients paid the full
drug costs while in the doughnut hole before the ACA (Fig 2). Out-of-
pocket costs varied little, with the range between the upper and lower
quartiles across all drugs and formularies equal to $82 on average.
After the doughnut hole is closed in 2020, we estimate that median
out-of-pocket costs would still be high, with an average of $5,663
across all products (a savings of approximately $2,550 per year).
In the base case analysis, we assumed that drug prices will not
change between 2010 and 2020. To evaluate the impact of drug
Table 1. Monthly Formulary Price for Orally Administered Chemotherapy Offered by Medicare Part D Formularies in 2014 and Median Duration of Drug Use
Drug
Median
Monthly
Price ($)
25th Percentile
of Monthly
Price ($)
75th Percentile
of Monthly
Price ($)
Median
Duration of
Use (months)
Abiraterone 7,009 6,956 7,089 8
Afatinib 6,279 6,211 6,319 11
Axitinib 10,057 9,920 10,183 7
Cabozantinib 10,888 10,770 10,960 7
Crizotinib 11,908 11,816 12,016 8
Dabrafenib 8,359 8,269 8,414 5
Dasatinib 9,516 9,413 9,633 12
Enzalutamide 8,128 8,046 8,132 9
Erlotinib 6,353 6,313 6,417 11
Everolimus 9,976 9,877 10,034 5
Imatinib 7,832 7,764 7,898 12
Lapatinib 5,123 5,073 5,176 9
Lenalidomide 13,683 13,537 13,779 4
Nilotinib 9,543 9,480 9,655 12
Pazopanib 7,924 7,843 7,904 8
Pomalidomide 16,093 15,923 16,202 8
Regorafenib 15,206 15,020 15,213 3
Sorafenib 10,811 10,728 10,937 6
Sunitinib 13,003 12,919 13,170 12
Trametinib 9,564 9,466 9,632 5
Vandetanib 11,421 11,304 11,502 12
Vemurafenib 11,241 11,071 11,355 5
Vorinostat 11,469 11,312 11,609 4
NOTE. Prices are from the Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files available through the Centers for Medicare & Medicaid
Services and represent the plan level averagemonthly reimbursement (amount paid from all sources [patient, plan, andMedicare]) for formulary Part D drugs for a 30-day
supply of themost commonly covered dose of each drug selected.Median costs were calculated across all plans, and interquartile ranges are indicated. Median duration
of usewas obtained from data provided in Howard et al.15 For products not included in Howard et al, we used the drug product label to identifymedian duration of therapy
(Data Supplement).
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price increases or decreases, we varied the drug price by6 50% for
the 2020 estimate. We found that if prices declined by 50%, average
out-of-pocket costs would be $3,738, which would save benefi-
ciaries an average of $4,468 per year in 2020 compared with 2010
costs (Table 3). However, if drug prices increased by 50%, average
out-of-pocket costs would be $7,584, which would save benefi-
ciaries only $621 over the 2010 prices (Table 3).
DISCUSSION
Medicare beneficiaries who do not receive low-income subsidies
and who need to use cancer medications long term will spend
approximately $4,000 to $10,000 out of pocket, depending on
the therapy prescribed, even after the doughnut hole is closed. In
2012, the average Medicare beneficiary’s household budget was
estimated at $33,993.17 By taking into consideration the mean
annual expenditures of $11,673 for housing, $5,189 for food, and
$5,087 for transportation, let alone other health care costs, few can
afford the high costs of specialty cancer therapies.
In 2014, 37 million beneficiaries were enrolled in a Medicare
drug plan. Although 30% of Part D enrollees receive low-income
subsidies through dual eligibility for Medicaid or through other
needs-based qualifications (eg, annual income of, $17,235 for an
individual or, $23,265 for a couple), those who do not qualify for
subsidies have few options for affordable care.18 In fact, Medigap
policies and out-of-pocket limits on Medicare Advantage plans
meant to limit cost sharing for Medicare beneficiaries exclude Part
D spending, which further exposes beneficiaries to high costs.18-20
High out-of-pocket expenditures negatively affect patient
adherence to oral cancer therapies.21-23 Even in the setting of
relatively low out-of-pocket costs, such as endocrine therapy
for breast cancer, large declines have been seen in adherence as
patients move into the doughnut hole and face larger cost sharing,
with subsequent rebounds in adherence as out-of-pocket prices
reduce.22 Even in the catastrophic phase of the Medicare Part D
benefit, enrollees are expected to contribute 5% toward the price of
their medications. Even this generous level of cost sharing results in
high costs to patients. The average price across orally administered
cancer therapies covered by Medicare in 2014 was more than
$10,000 per month of therapy, with 5% cost sharing resulting in
$500 out of pocket per month for the beneficiary.
One recently published study of total and out-of-pocket
spending on specialty medications among Medicare Advantage
plan members suggested that large decreases in out-of-pocket
spending follow the initial phases of the doughnut hole closure.11
The authors observed a 26% reduction in out-of-pocket spending
between 2010 and 2011 across all drugs that met the $600 per
specialty tier threshold. The study also highlighted the benefits of
closing the doughnut hole on average but did not address the
Table 2. Common Formulary Structures Used by Stand-Alone Part D and Medicare Advantage Part D Plan/Product Formularies for Orally Administered Cancer
Medications in 2014
Benefit Structure
$310 Deductible,
25% Coinsurance
Initial, 45%
Coinsurance Gap,
5% Coinsurance
Catastrophic (%)
$0 Deductible, 33%
Coinsurance Initial,
45% Coinsurance
Gap, 5%
Coinsurance
Catastrophic (%)
$0 Deductible, 33%
Coinsurance Initial,
33% Coinsurance
Gap, 5%
Coinsurance
Catastrophic (%)
$0 Deductible, 25%
Coinsurance Initial,
45% Coinsurance
Gap, 5%
Coinsurance
Catastrophic (%)
Cumulative
Coverage of
Selected
Designs (%)
Drug PDP MA-PD PDP MA-PD PDP MA-PD PDP MA-PD PDP MA-PD
Abiraterone 45.6 12.6 43.4 48.3 3.3 15.1 0.4 5.3 92.7 81.3
Afatinib 45.7 13.0 43.3 45.5 3.3 17.6 1.2 6.5 93.5 82.6
Axitinib 45.7 12.7 43.2 45.9 3.3 16.3 1.0 7.0 93.2 81.9
Cabozantinib 45.7 13.0 43.3 45.4 3.3 17.6 1.2 6.6 93.5 82.6
Crizotinib 45.7 12.8 43.2 47.1 3.3 16.3 1.0 5.8 93.2 82.0
Dabrafenib 45.7 12.8 43.2 47.1 3.3 16.3 1.0 5.8 93.2 82.0
Dasatinib 45.3 12.5 44.8 44.2 3.2 21.8 0.4 6.0 93.7 84.5
Enzalutamide 45.6 12.5 43.4 48.6 3.3 15.1 0.4 4.8 92.7 81.0
Erlotinib 45.7 13.1 43.3 45.3 3.3 17.6 1.2 6.8 93.5 82.8
Everolimus 45.3 12.5 45.0 42.6 3.0 22.1 0.7 6.6 94.0 83.8
Imatinib 45.7 12.8 43.2 45.9 3.3 16.3 1.0 7.2 93.2 82.2
Lapatinib 45.7 12.6 43.4 48.4 3.3 15.1 0.5 5.3 92.9 81.4
Lenalidomide 45.3 12.7 44.8 44.3 3.2 21.9 0.4 5.7 93.7 84.6
Nilotinib 45.7 12.8 43.2 47.0 3.3 16.3 1.0 6.0 93.2 82.1
Pazopanib 45.6 12.6 43.4 47.6 3.3 15.1 0.4 5.9 92.7 81.2
Pomalidomide 45.4 12.8 44.0 45.3 3.3 19.2 0.7 6.5 93.4 83.8
Regorafenib 45.6 12.5 43.3 48.5 3.3 15.1 0.4 4.9 92.6 81.0
Sorafenib 45.6 12.6 43.4 47.6 3.3 15.1 0.8 5.8 93.1 81.1
Sunitinib 45.7 13.1 43.3 44.5 3.3 17.6 1.2 7.4 93.5 82.6
Trametinib 45.7 12.7 43.2 46.9 3.3 16.3 1.0 6.0 93.2 81.9
Vandetanib 45.7 13.0 43.2 47.8 3.3 16.7 1.0 4.2 93.2 81.7
Vemurafenib 45.6 12.6 43.4 48.4 3.3 15.1 0.4 5.0 92.7 81.1
Vorinostat 45.6 12.5 43.4 48.2 3.3 15.1 0.4 5.3 92.7 81.1
NOTE. Proportions reflect the percentage of plan/products that cover the relevant drug that uses the listed formulary structure. Analysis is based on the July 15, 2014,
quarterly release of the Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files from the Centers for Medicare & Medicaid Services.
Abbreviations: MA-PD, Medicare Advantage Part D Plan/Product formulary; PDP, Part D Plan/Product formulary.
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limitations of the policy for very-high-priced medications, which
include those that are the focus of the current report. Beneficiaries
who remain in the doughnut hole for the longest periods will receive
the most benefits of the policy change. A single fill for oral che-
motherapy prescriptions places the beneficiary in the doughnut hole,
andmost patients exit the doughnut hole at 1.6fills, which leaves little
time to gain benefits from this phase of coverage.
The current study has several important limitations. First, we
estimated use of only a single drug for each beneficiary in the
calculations. Given the age of the population, many beneficiaries
take additional medications aside from cancer therapies. These other
medications move the beneficiary through the doughnut hole faster,
with the same out-of-pocket maximums required. Thus, compar-
isons between the 2020 projected costs and the 2010 costs would not
be changed with the inclusion of other medications. Second, our
estimates of 2020 out-of-pocket costs are based on assumptions that
the benefit design is only changed through a reduction of patient cost
sharing from 100% to 25% and inclusion of the 50% manufacturer
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Fig 2. Median total out-of-pocket costs
for a course of oral anticancer therapies for
Part D beneficiaries by drug before (2010)
and after (2020) the doughnut hole closes,
with the assumption of a median duration
treatment course. Analysis is based on the
July 15, 2014, quarterly release of the
Prescription Drug Plan Formulary, Phar-
macy Network, and Pricing Information
Files from the Centers for Medicare &
Medicaid Services. Input price is from the
formulary files and represents the average
reimbursed amount across each plan for
the product listed for 1 month of therapy at
the mean recommended dose. Median
duration of use was obtained from data
provided in Howard et al.15 For products
not included in Howard et al, we used the
drug product label to identify median
duration of therapy (Data Supplement).
Table 3. Median Total Patient OOP Cost Savings for a Course of Oral Anticancer Therapies for Closing the Doughnut Hole Under Varying Assumptions With Regard to
Drug Pricing
2010
Base Case
(No Change in Price; $) 50% Price Increase ($) 50% Price Decrease ($)
Drug
Estimated
OOP 2010
Estimated
OOP 2020
Savings
From 2010
Estimated
OOP 2020
Savings
From 2010
Estimated
OOP 2020
Savings
From 2010
Abiraterone 7,156 4,621 2,535 6,023 1,133 3,220 3,936
Afatinib 7,817 5,242 2,575 6,968 849 3,532 4,285
Axitinib 7,877 5,345 2,532 7,108 769 3,582 4,295
Cabozantinib 8,174 5,597 2,577 7,508 666 3,709 4,465
Crizotinib 9,120 6,552 2,568 8,917 203 4,187 4,933
Dabrafenib 6,454 3,889 2,565 4,923 1,531 2,855 3,599
Dasatinib 10,075 7,531 2,544 10,386 (311) 4,676 5,399
Enzalutamide 8,002 5,480 2,522 7,320 682 3,646 4,356
Erlotinib 7,853 5,309 2,544 7,054 799 3,563 4,290
Everolimus 6,836 4,291 2,545 5,525 1,311 3,056 3,780
Imatinib 9,062 6,508 2,554 8,855 207 4,162 4,900
Lapatinib 6,660 4,121 2,539 5,280 1,380 2,970 3,690
Lenalidomide 7,084 4,561 2,523 5,932 1,152 3,189 3,895
Nilotinib 10,083 7,545 2,538 10,410 (327) 4,680 5,403
Pazopanib 7,518 4,981 2,537 6,566 952 3,400 4,118
Pomalidomide 10,800 8,223 2,577 11,451 (651) 5,006 5,794
Regorafenib 6,630 4,099 2,531 5,242 1,388 2,959 3,671
Sorafenib 7,598 5,063 2,535 6,696 902 3,440 4,158
Sunitinib 12,163 9,623 2,540 13,528 (1,365) 5,721 6,442
Trametinib 6,756 4,188 2,568 5,371 1,385 3,005 3,751
Vandetanib 11,218 8,650 2,568 12,092 (874) 5,230 5,988
Vemurafenib 7,149 4,623 2,526 6,029 1,120 3,221 3,928
Vorinostat 6,650 4,112 2,538 5,259 1,391 2,965 3,685
NOTE. Analysis is based on the July 15, 2014, quarterly release of the Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files from the
Centers for Medicare &Medicaid Services. Input price is from the formulary files and represents the average reimbursed amount across each plan for the product listed
for 1 month of therapy at the mean recommended dose. Savings in the base case scenario are attributed to the 50% manufacturer discount during the doughnut hole.
These contributions from the manufacturer are included in the patient out-of-pocket limit of $4,700. After reaching this limit, beneficiaries pay 5% of the drug price until
the beginning of the next calendar year.
Abbreviation: OOP, out of pocket.
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discount toward the out-of-pocket maximum during the coverage
gap. However, prices paid to manufacturers for oral chemotherapies
have increased significantly over time. At the same time, newer
policies related to increasing biologic competition and the intro-
duction of generics could result in price reductions for some
therapies, although the extent of cost savings through this form of
competition currently is not clear.24,25 To address these conflicting
scenarios, in sensitivity analyses, we varied the drug input price by
increasing and decreasing drug prices by 50%. These price changes
had little impact on the relative effect of the doughnut hole closing
on patient out-of-pocket spending, but they did have an impact on
the accumulated annual cost to patients, as would be expected.
Finally, beneficiaries who use patient assistance programs or those
eligible for low-income subsidies or Medicaid were not considered
because their out-of-pocket costs differ from those of patients
without these protections.
Out-of-pocket costs for orally administered cancer medications
for Medicare Part D beneficiaries without low-income subsidies are
very high and will remain so after the doughnut hole is closed. We
found almost no variation in out-of-pocket costs to patients across all
available formularies, which suggests that patients who need these
products can do little to reduce their out-of-pocket costs through
better plan selection. With consideration of the rising prices for
specialty drugs over the past decade,26 any projected cost savings from
closing the doughnut hole likely would be lost for these drugs. Efforts
should be made to improve affordability of specialty drugs for
Medicare beneficiaries given that medication nonadherence and a
forgoing of basic needs are associated with high out-of-pocket
medication costs.21,23,27,28 In particular, some key protections
offered to privately insured individuals through the ACA are
unavailable to Medicare-insured beneficiaries, specifically those on
traditional Medicare plans. These include the annual out-of-pocket
maximum that includes both medical and pharmacy spending
($6,600 for an individual in 2015). The current findings demonstrate
the extraordinary financial burden of orally administered cancer
medications for Medicare Part D enrollees and the need for policies
that improve access to high-value therapies. Examples of such policies
are a substantial lowering of drug prices or a shift in formulary
designs from coinsurance to copayments.
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